curcumin has been researched along with Candidiasis--Oral* in 6 studies
1 trial(s) available for curcumin and Candidiasis--Oral
Article | Year |
---|---|
Comparison between two antimicrobial photodynamic therapy protocols for oral candidiasis in patients undergoing treatment for head and neck cancer: A two-arm, single-blind clinical trial.
Purpose This study aimed to compare the efficacy of Antimicrobial Photodynamic Therapy (aPDT) with 300 µmol/L of methylene blue and 8 µmol/L of curcumin on oral candidiasis patients with HNSCC undergoing treatment. Methods A two-arm, single-blind clinical trial was performed. Following verification for eligibility (n = 447), 108 patients were included in the study. The study consisted of a group that received aPDT with methylene blue (n = 57) and another that received aPDT with curcumin (n = 51). The patients rinsed their mouths with an aqueous solution of 300 µmol/L of methylene blue and 8 µmol/L of curcumin in four sessions, and then the lesion was scraped for the subsequent RT-qPCR. The primary outcome was that no cure was presented for oral candidiasis after treatment. The secondary result was reducing the number of sites affected by oral candidiasis. Results There was no difference in treatment failure evaluated by the necessity of drug prescription or Candida sp DNA quantification. However, clinically the methylene blue protocol reduced the number of infected anatomical sites compared to the curcumin protocol. Conclusion Methylene blue aPDT reduced the number of infected anatomical sites compared to curcumin. Topics: Anti-Bacterial Agents; Anti-Infective Agents; Candidiasis, Oral; Curcumin; Head and Neck Neoplasms; Humans; Methylene Blue; Photochemotherapy; Photosensitizing Agents; Single-Blind Method | 2022 |
5 other study(ies) available for curcumin and Candidiasis--Oral
Article | Year |
---|---|
Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis.
Phytotherapeutics is widely used nowadays as an alternative to the current antifungal drugs to reduce their side effects. Curcumin, with its wide therapeutic array as antioxidant and anti-inflammatory agent, is one of the natural compounds that ha..s an antifungal effect, especially when being used at nanoscale to increase its bioavailability. Our research aimed to evaluate clinically and microbiologically the effect of using topical nanocurcumin suspension to treat oral candidiasis. After 4 days from induction of oral candidiasis (baseline), we randomly divided 39 female BALB/c mice into three groups of 13 animals; nanocurcumin, nystatin, and sham groups. All animals in nanocurcumin and nystatin groups received topical treatment twice daily for 10 days. Then, we performed clinical and microbiological evaluations at baseline, day 5, and day 10. By the end of treatment, our results revealed that nanocurcumin promoted a significant reduction in the number of candida colonies. There was no statistically significant difference neither clinically nor microbiologically between nanocurcumin and nystatin groups. In conclusion, nanocurcumin has a good antifungal effect as nystatin, however, its therapeutic efficacy takes a longer time to appear than nystatin. The enhanced bioavailability of curcumin at the nanoscale qualifies this nano-herb as a promising alternative therapy for oral candidiasis, evading nystatin-associated morbidity. Topics: Animals; Antifungal Agents; Candidiasis, Oral; Curcumin; Female; Mice; Nanoparticles; Nystatin | 2023 |
The treatments of oral candidiasis involve azole-based antifungals; however, the fungal resistance of these drug compounds has been detected in worldwide. Therefore, the discovery of new molecules from natural sources, such as curcumin, has been reported for the treatment of fungal diseases. However, this drug has poor solubility in aqueous solvents and presents low bioavailability. Thus, the system was designed for a low viscosity precursor of a liquid crystal phase, and saliva leads a phase behaviour increasing the viscosity of system and the residence time in the mucosa and promotes antifungal activity Formulation composed of PPG-5-CETETH-20, oleic acid and water (30, 30, 40% w/w) denominated F. This formulation was diluted with artificial saliva at 10, 20 and 30% (w/v). These formulations were characterized by polarized light microscopy (PLM), mechanical behaviour, oscillatory rheology and performance studies on mucosa. Topics: Administration, Buccal; Animals; Candidiasis, Oral; Curcumin; Drug Delivery Systems; Liquid Crystals; Scattering, Small Angle; Swine; X-Ray Diffraction | 2019 |
Antimicrobial Photodynamic Therapy Mediated by Curcumin-Loaded Polymeric Nanoparticles in a Murine Model of Oral Candidiasis.
Antimicrobial photodynamic therapy (aPDT) has been proposed as an alternative method for oral candidiasis (OC), while nanocarriers have been used to improve the water solubility of curcumin (CUR). The aim of this study is to encapsulate CUR in polymeric nanoparticles (NPs) and to evaluate its photodynamic effects on a murine model of OC. Anionic and cationic CUR-NP is synthesized using poly-lactic acid and dextran sulfate and then characterized. Female mice are immunosuppressed and inoculated with Topics: Animals; Antifungal Agents; Biomarkers; Candida albicans; Candidiasis, Oral; Curcumin; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Female; Immunohistochemistry; Mice; Microbial Sensitivity Tests; Nanoparticles; Photochemotherapy; Polymers | 2018 |
Curcumin-mediated photodynamic inactivation of Candida albicans in a murine model of oral candidiasis.
In vitro investigations of curcumin-mediated photodynamic therapy (PDT) are encouraging, but there is a lack of reliable in vivo evidence of its efficacy. This study describes the photoinactivation of Candida albicans in a murine model of oral candidiasis, using curcumin as a photosensitizer. Forty immunosuppressed mice were orally inoculated with C. albicans and after five days, they received topical curcumin (20, 40 and 80 μM) and illumination with LED light. The use of curcumin or light alone were also investigated. Positive control animals did not receive any treatment and negative control animals were not inoculated with C. albicans. The number of surviving yeast cells was determined and analyzed by ANOVA and Tukey's post-hoc test (α = 0.05). Histological evaluation of the presence of yeast and inflammatory reaction was also conducted. All exposures to curcumin with LED light caused a significant reduction in C. albicans viability after PDT, but the use of 80 μM curcumin associated with light was able to induce the highest log10 reduction in colony counts (4 logs). It was concluded that curcumin-mediated PDT proved to be effective for in vivo inactivation of C. albicans without harming the host tissue of mice. Topics: Administration, Topical; Animals; Candida albicans; Candidiasis, Oral; Colony Count, Microbial; Curcumin; Disease Models, Animal; Female; Light; Mice; Photochemotherapy; Photosensitizing Agents; Treatment Outcome | 2013 |
Effects of curcumin on lung histopathology and fungal burden in a mouse model of chronic asthma and oropharyngeal candidiasis.
Oropharyngeal candidiasis (OPC) is one of the most common local side effects of current therapy in chronic asthma. New therapeutic options with fewer side effects and reverse chronic changes are needed. Curcumin, as a promising antiinflammatory and antifungal agent, could be a candidate of alternative therapy in asthma. This study aimed to determine the efficacy of orally administrated curcumin on lung histopathology, serum nitric oxide levels and fungal burden in a murine model of asthma and OPC.. Thirty five BALB/c mice were divided into five groups: I, II, III, IV (placebo) and V (control). All groups except the control were sensitized and challenged with ovalbumin. OPC model was established after the model of chronic asthma. Lung histology, serum nitric oxide levels and fungal burden were evaluated after 5 days of treatment with curcumin, dexamethasone, curcumin-dexamethasone combination and placebo. Evaluation of lung histology included subepithelial smooth muscle and epithelial thickness and number of goblet and mast cells by using light microscopy.. All histological parameters improved in curcumin group similar to dexamethasone group. Curcumin and dexamethasone-curcumin combination were also as effective as dexamethasone on decreasing nitric oxide levels. Oral fungal burden was significantly lower in curcumin-treated group than dexamethasone.. In our study we demonstrated that curcumin administration alleviates the pathological changes in asthma and decreases the fungal burden. Curcumin may have a potential effect on treating chronic asthma and decreasing the frequency of the OPC. Topics: Animals; Anti-Inflammatory Agents; Asthma; Candidiasis, Oral; Colony Count, Microbial; Curcumin; Dexamethasone; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Lung; Male; Mice; Mice, Inbred BALB C; Nitric Oxide; Ovalbumin; Tongue | 2011 |